タナカ ジユンジ   TANAKA Junji
  田中 淳司
   所属   医学部 医学科(東京女子医科大学病院)
   職種   教授・基幹分野長
論文種別 原著
言語種別 英語
査読の有無 査読あり
表題 Comparison of Autologous and Unrelated Transplants for Cytogenetically Normal Acute Myelogenous Leukemia.
掲載誌名 正式名:Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
略  称:Biol Blood Marrow Transplant
ISSNコード:(1523-6536)1083-8791(Linking)
掲載区分国外
巻・号・頁 23(9),pp.1447-1454
著者・共著者 Mizutani Motonori†, Takami Akiyoshi, Hara Masahiko, Mizuno Shohei, Yanada Masamitsu, Chou Takaaki, Uchiyama Hitoji, Ohashi Kazuteru, Miyamoto Toshihiro, Ozawa Yukiyasu, Imataki Osamu, Kobayashi Naoki, Uchida Naoyuki, Kanamori Heiwa, Kamimura Tomohiko, Eto Tetsuya, Onizuka Makoto, Tanaka Junji, Atsuta Yoshiko, Yano Shingo
発行年月 2017/09
概要 Allogeneic stem cell transplantation (SCT) from an HLA-matched sibling donor (MSD) is a postremission treatment that offers a potential cure for adults with cytogenetically normal (CN) acute myelogenous leukemia (AML) in first complete remission (CR1). The best alternative in the absence of an MSD remains unclear, however. The aim of this study was to retrospectively compare the outcomes of autologous peripheral blood stem cell transplantation (auto-PBSCT; n = 177) and allogeneic bone marrow transplantation (BMT) from an HLA-matched unrelated donor (MUD; n = 173) in adult patients with CN-AML/CR1. Both the multivariate analysis (hazard ratio [HR], 1.18; 95% confidence interval [CI], 0.71 to 1.97; P = .53) and propensity score models (HR, 1.40; 95% CI, 0.80 to 2.43; P = .24) indicated that the leukemia-free survival (LFS) rate of auto-PBSCT was not significantly different from that of MUD-BMT. These results suggest that in the absence of an available MSD, auto-PBSCT remains a viable alternative as postremission therapy in patients with CN-AML/CR1.
DOI 10.1016/j.bbmt.2017.05.008
PMID 28533061